Antony Mersiades Clinical Oncology Society of Australia Annual Scientific Meeting 2018

Abstracts this author is presenting:

• Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV) — Poster Session 2
• A Phase 2 trial of durvalumab and tremelimumab with chemotherapy in metastatic EGFR mutant non-small cell lung cancer following progression on EGFR tyrosine kinase inhibitors (ILLUMINATE) — Poster Session 2
• Phase II trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancer (Oscillate) — Poster Session 2
• A randomised open-label phase 2 trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after concurrent chemo-radiotherapy (STIMULI) — Poster Session 2
• PEARL: A randomised phase 3 trial of early referral to palliative care (PC) for patients with advanced thoracic malignancies. — Poster Session 2
• NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy (SABR) in advanced non-small cell lung cancer (NSCLC), progressing after first or second line chemotherapy — Poster Session 2